Short Interest in IPSEN (OTCMKTS:IPSEY) Grows By 2,000.0%

Key Points

• IPSEN (OTCMKTS:IPSEY) experienced a significant increase in short interest, rising by 2,000.0% from 200 to 4,200 shares between August 15th and August 31st.
• The current short-interest ratio for IPSEN is 1.6 days, based on an average daily trading volume of 2,600 shares.
• As of Thursday, IPSEN's stock price remained flat at $34.85, with a 1-year range of $25.11 to $34.96.

IPSEN (OTCMKTS:IPSEY - Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totaling 4,200 shares, a growth of 2,000.0% from the August 15th total of 200 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 2,600 shares, the days-to-cover ratio is currently 1.6 days. Based on an average daily volume of 2,600 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.0% of the shares of the stock are sold short.

IPSEN Trading Down 1.5%

Shares of IPSEY stock traded down $0.53 during trading hours on Tuesday, hitting $34.55. 1,616 shares of the company's stock were exchanged, compared to its average volume of 3,721. IPSEN has a 12-month low of $25.11 and a 12-month high of $35.08. The business's 50 day simple moving average is $32.56 and its 200-day simple moving average is $30.26.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.